Complete response of advanced HER2-amplified lung adenocarcinoma to cadonilimab combined with disitamab vedotin: a case report
Treatment with cadonilimab and disitamab vedotin induced a sustained complete response in a patient with advanced HER2-amplified lung adenocarcinoma who declined chemotherapy. Thus, this combination therapy may offer a promising, effective, and well-tolerated treatment alternative for similar patients. Further clinical trials are warranted to validate these findings and potentially establish a new standard of care for this subset of lung cancer patients.
Authors
- Zhuying Li (ORCID: https://orcid.org/0000-0001-5474-6949)
- Keru Ma (ORCID: https://orcid.org/0000-0003-3397-5667)
- Zongying Liu (ORCID: https://orcid.org/0000-0003-3658-3511)
- Yue Li (ORCID: https://orcid.org/0000-0002-3964-5645)
- Hao Wang (ORCID: https://orcid.org/0000-0002-3294-8678)
Institutions
- Harbin Medical University (CN)
- First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3389/fonc.2025.1587210
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00